Seres 10-Q: $16.3M Q3 Loss, $17.5M Cash, Going Concern Reaffirmed
MCRB is trading near its 52-week low of $1.675 (12% above the low).
Summary
Seres posted a $16.3 million third-quarter loss and held $17.5 million in cash, with management repeating that substantial doubt exists about its ability to continue as a going concern and that it will need funding after Q1 2027.
Key Events · Earnings and Guidance · MCRB
-
Q3 Loss of $16.3 Million
Net loss was $16.3 million ($1.63 per share) on grant revenue of $0.6 million, with R&D at $5.6 million and G&A at $5.4 million.
-
Cash of $17.5 Million, Funding Needed After Q1 2027
Cash and equivalents stood at $17.5 million at September 30, 2026; including the $12.5 million milestone payment received in October 2026, the company expects to require additional funding following the first quarter of 2027.
-
Going Concern Doubt Reaffirmed
Management concluded substantial doubt exists about the ability to continue as a going concern for 12 months from issuance, because financing and partnership options are outside its control and cannot be counted as probable.
-
$11.5 Million Non-Cash Lease Impairments
Impairment of long-lived assets was $11.5 million for the nine months, tied to the Sidney Street lease termination and the 101 Cambridgepark lease amendment; these are non-cash charges.
Analysis · MCRB · Life Sciences
The number that matters here is cash burn, not the accounting loss. Seres closed September 30 with $17.5 million in cash against a $16.3 million third-quarter net loss, and management again concluded substantial doubt exists about the company's ability to continue as a going concern. Even counting the $12.5 million Nestlé milestone payment received in October 2026, it expects to need new funding after the first quarter of 2027. The quarter also carried $5.7 million of non-cash impairment charges on leased space the company exited. With the SER-155 Phase 2 study in allo-HCT paused for lack of funding and the CFO departing November 15, survival now hinges on a partnership or capital raise it has not yet secured.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCRB was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. The 52-week trading range was $1.68 to $29.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.